Le Lézard
Classified in: Health
Subjects: POL, AVO

Nurse Practitioners Commend Trump Administration's Recommendations on Scope of Practice Laws


AUSTIN, Texas, Dec. 4, 2018 /PRNewswire/ -- Today, the American Association of Nurse Practitioners (AANP) issued the following statement regarding the Administration's recent release of a report entitled Reforming America's Healthcare System through Choice and Competition. Prepared by the Department of Health and Human Services (HHS) in cooperation with the Departments of Treasury and Labor, and the Federal Trade Commission, the report describes the extent to which state and federal laws, regulations, guidance, and policies discourage choice and competition in health care markets.

American Association of Nurse Practitioners (PRNewsfoto/American Association of Nurse P)

According to the report, "States should consider changes to their scope-of-practice statutes to allow all healthcare providers to practice to the top of their license" utilizing their full skillset. The report further notes, "economic analysis indicates that expanding APRN SOP, consistent with APRN education, training, and experience, would have clear consumer benefits, particularly in rural and poorer areas."

"We commend the Administration's efforts to ensure access to high-quality care is not harmed by needless barriers to practice. We wholeheartedly agree that outdated scope of practice laws need to be removed and all healthcare providers should practice to the top of their license, utilizing their full skill set," said Joyce M. Knestrick, Ph.D., APRN, C-FNP, FAANP, President of AANP. "We share the aim of the Administration that we all should be working together striving to create a health care system that works for patients and providers alike. We are encouraged and agree with the Administration's recommendation that patients suffer when faced with barriers to access resulting from outdated scope of practice laws."

"The report's acknowledgment adds to the growing chorus and the body of research showing that patients and families greatly benefit from expanded access to NP-provided care. We look forward to continuing our work with state and federal lawmakers to increase patient access to affordable, high-quality care across the country," said David Hebert, CEO of AANP. "We call on the Administration to take further action toward retiring needless barriers to care for patients and request the Secretary use his regulatory authority to help make these changes. AANP looks forward to working with the Administration, Congress, and state legislatures to ensure patients have access to health care delivered by their provider of choice."

The American Association of Nurse Practitioners (AANP) is the largest professional membership organization for nurse practitioners (NPs) of all specialties. It represents the interests of the more than 248,000 licensed NPs in the U.S. AANP provides legislative leadership at the local, state and national levels, advancing health policy; promoting excellence in practice, education and research; and establishing standards that best serve NP patients and other health care consumers. As The Voice of the Nurse Practitioner®, AANP represents the interests of NPs as providers of high-quality, cost-effective, comprehensive, patient-centered health care. For more information and to locate an NP in your community, visit WeChooseNPs.org.

 

SOURCE American Association of Nurse Practitioners


These press releases may also interest you

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...

3 jui 2024
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...

3 jui 2024
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...

3 jui 2024
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...



News published on and distributed by: